CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ibrutinib (Imbruvica) for Lymphoma

Brand Name Imbruvica
Generic Name Ibrutinib
Tumour Type Lymphoma
Indication In combination with rituximab for Waldenstrom's Macroglobulinemia
Review Status Not Filed
Manufacturer Janssen Canada Inc.
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
Last Updated July 17, 2019